A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free survival after daratumumab maintenance therapy in transplant eligible participants with previously untreated Multiple Myeloma.
Epistemonikos ID: 4568d26b5d49e8bfa742622d61ed0e27bf677028
First added on: Feb 01, 2021